|
(Health-NewsWire.Net, August 13, 2015 ) Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline
RnRMarketResearch.com Adds “Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021” which provides an overview of the Anti-hypertensive Therapeutics.
Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control.
The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB), beta-blockers, renin inhibitors, and diuretics. The percentage of patients treated using monotherapy and combination therapy (including fixed-dose combinations) varies from country to country. The most commonly prescribed drugs in the CCB class are amlodipine and lercanidipine, while the leading ARBs are telmisartan, candesartan, olmesartan, irbesartan, losartan, valsartan, azilsartan medoxomil, and eprosartan. Ramipril, imidapril, perindopril, enalapril, lisinopril, benazepril, fosinopril, trandolapril, and quinapril dominate the ACEIs. in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline.
Complete report on, “Anti-hypertensive Therapeutics” addition with 20 market data tables and 33 figures, spread across 82 pages is http://www.rnrmarketresearch.com/anti-hypertensive-therapeutics-in-asia-pacific-markets-to-2021-increasing-prevalence-of-hypertension-drives-market-growth-despite-weak-pipeline-market-report.html .
Scope :
• Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
• Will generics continue to dominate treatment?
• How do the elderly populations and their associated risk factors affect prevalence?
• The current anti-hypertensive therapeutics pipeline is weak, comprising 124 molecules in various stages of development, dominated by small molecules.
• Will the upcoming molecules change the treatment paradigm in the near future?
• How will the weak pipeline affect the market?
• Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition.
• How do failure rates vary by product stage of development, molecule type, and mechanism of action?
• How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
• Over the 2014-2021 forecast periods, the APAC anti-hypertensive therapeutics market is expected to increase in value at a CAGR of 3.4% from $15.7 billion to just over $19.9 billion. Growth is projected to vary considerably across the four assessed markets.
• Which markets make the most significant contribution to the current market size?
• What are the epidemiology trends in these markets?
• Will branded products' patent expirations pose a significant threat?
• Will new market entrants over the forecast period lead to substantial changes in annual therapy costs?
Inquire for discount http://www.rnrmarketresearch.com/contacts/discount?rname=403220 . (This is a premium report price at US$4995 for a single user PDF license)
Reasons to buy :
• Understand the clinical context of hypertension by considering symptoms, etiology, pathophysiology, co-morbidities and complications, epidemiology, diagnosis, and treatment options.
• Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape, and recognize gaps.
• Appreciate key anti-hypertensive pipeline trends in molecule type, administration route, mechanism of action, and novelty.
• Consider market opportunities and potential risks by examining trends in anti-hypertensive clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
• Compare treatment usage patterns, annual therapy costs, and market growth projections for the China, India, Australia, and Japan.
• Discover trends in licensing and co-development deals concerning anti-hypertensive products and identify the major strategic consolidations that have shaped the commercial landscape.
Explore More Research Report on Hypertension Drugs Market.
The Hypertension Drugs That Can Make A Difference
Hypertension refers to high blood pressure and is a medical ailment that needs to be taken proper care of as it can lead to a lot of other problems. There are a lot of hypertension drugs that you can find in various pharmacy stores. The main purpose of these drugs is to lower the levels of blood pressure and thus restore the body balance.
With increase in blood pressure, the problems can be extensive. The brain finds it hard to function normally as the balance of the body is disturbed. The blood sugar levels may rise steeply and the pulse accelerates as well.
Hence, make sure to explore the details of the various drugs that are bound to be effective for dealing with problems of increasing blood pressure. Most of these drugs have been medically tested and it is only after the results have been positive that patients are allowed to use these drugs.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
